# Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

> **NCT04767906** · PHASE2 · COMPLETED · sponsor: **University of Leipzig** · enrollment: 16 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT04767906
- **Lead sponsor:** University of Leipzig
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767906, "Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04767906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*